Premier Biomedical (BIEI) Stock Price, News & Analysis

Company Overview

Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.

Key Stats

• Today's Range: $0.0005 to $0.0006
• 50-Day Range: N/A
• 52-Week Range: $0.0003 to $0.0021
• Volume: 7.88 million shs
• Average Volume: 4.09 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Premier Biomedical Stock Analysis - MarketRank™

Premier Biomedical scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Premier Biomedical.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Premier Biomedical is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Premier Biomedical is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Premier Biomedical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Premier Biomedical has recently decreased by 15.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Premier Biomedical does not currently pay a dividend.

Dividend Growth

Premier Biomedical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Premier Biomedical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Premier Biomedical has recently decreased by 15.93%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Premier Biomedical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Premier Biomedical this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Premier Biomedical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Premier Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.78% of the stock of Premier Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

BIEI Stock Analysis - Frequently Asked Questions

How have BIEI shares performed this year?

Premier Biomedical's stock was trading at $0.0007 at the start of the year. Since then, BIEI stock has decreased by 28.6% and is now trading at $0.0005.
View the best growth stocks for 2025 here.

How do I buy shares of Premier Biomedical?

Shares of BIEI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Premier Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Premier Biomedical investors own include Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), CytoDyn (CYDY), Vaxart (VXRT), Arcturus Therapeutics (ARCT) and Actinium Pharmaceuticals (ATNM).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BIEI
• CIK: 1515740
• Web: www.premierbiomedical.com
• Phone: 724-633-7033
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A